Incorporation of Levodopa into Biopolymer Coatings Based on Carboxylated Carbon Nanotubes for PH-Dependent Sustained Release Drug Delivery

Overview

Journal Nanomaterials (Basel)

Date 2018 Jun 3

PMID 29857532

Citations 7

Authors

Julia Meihua Tan

Bullo Saifullah

Aminu Umar Kura

Sharida Fakurazi

Mohd Zobir Hussein

Affiliations

Soon will be listed here.

Abstract

Four drug delivery systems were formulated by non-covalent functionalization of carboxylated single walled carbon nanotubes using biocompatible polymers as coating agent (i.e., Tween 20, Tween 80, chitosan or polyethylene glycol) for the delivery of levodopa, a drug used in Parkinson's disease. The chemical interaction between the coating agent and carbon nanotubes-levodopa conjugate was confirmed by Fourier transform infrared (FTIR) and Raman studies. The drug release profiles were revealed to be dependent upon the type of applied coating material and this could be further adjusted to a desired rate to meet different biomedical conditions. In vitro drug release experiments measured using UV-Vis spectrometry demonstrated that the coated conjugates yielded a more prolonged and sustained release pattern compared to the uncoated conjugate. Cytotoxicity of the formulated conjugates was studied by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay using normal mouse embryonic fibroblast 3T3 cell line. Compared to the non-coated conjugate, the MTT data indicated that the coating procedure improved the biocompatibility of all systems by 34⁻41% when the concentration used exceeded 100 μg/mL. In conclusion, the comprehensive results of this study suggest that carbon nanotubes-based drug carrier coated with a suitable biomaterial may possibly be a potential nanoparticle system that could facilitate drug delivery to the brain with tunable physicochemical properties.

Citing Articles

Dual targeting multiwalled carbon nanotubes for improved neratinib delivery in breast cancer.

Lila A, Bhattacharya R, Moin A, Al Hagbani T, Abdallah M, Danish Rizvi S RSC Adv. 2023; 13(35):24309-24318.

PMID: 37583664 PMC: 10424192. DOI: 10.1039/d3ra04732f.

The Management of Parkinson's Disease: An Overview of the Current Advancements in Drug Delivery Systems.

Nakmode D, Day C, Song Y, Garg S Pharmaceutics. 2023; 15(5).

PMID: 37242745 PMC: 10223383. DOI: 10.3390/pharmaceutics15051503.

Cytotoxicity of Carbon Nanotubes, Graphene, Fullerenes, and Dots.

Kharlamova M, Kramberger C Nanomaterials (Basel). 2023; 13(9).

PMID: 37177003 PMC: 10180519. DOI: 10.3390/nano13091458.

Multifaceted nanoparticles: emerging mechanisms and therapies in neurodegenerative diseases.

Mistretta M, Farini A, Torrente Y, Villa C Brain. 2023; 146(6):2227-2240.

PMID: 36729638 PMC: 10232254. DOI: 10.1093/brain/awad014.

Fmoc-PEG Coated Single-Wall Carbon Nanotube Carriers by Non-covalent Functionalization: An Experimental and Molecular Dynamics Study.

Yeniyurt Y, Kilic S, Guner-Yilmaz O, Bozoglu S, Meran M, Baysak E Front Bioeng Biotechnol. 2021; 9:648366.

PMID: 34055757 PMC: 8160473. DOI: 10.3389/fbioe.2021.648366.

References

Hoffman W, Jump A . Tween 20 removes antibodies and other proteins from nitrocellulose. J Immunol Methods. 1986; 94(1-2):191-6. DOI: 10.1016/0022-1759(86)90232-2. View

Gelperina S, Maksimenko O, Khalansky A, Vanchugova L, Shipulo E, Abbasova K . Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur J Pharm Biopharm. 2009; 74(2):157-63. DOI: 10.1016/j.ejpb.2009.09.003. View

Dwibhashyam V, Nagappa A . Strategies for enhanced drug delivery to the central nervous system. Indian J Pharm Sci. 2010; 70(2):145-53. PMC: 2792490. DOI: 10.4103/0250-474X.41446. View

Vitale F, Summerson S, Aazhang B, Kemere C, Pasquali M . Neural stimulation and recording with bidirectional, soft carbon nanotube fiber microelectrodes. ACS Nano. 2015; 9(4):4465-74. DOI: 10.1021/acsnano.5b01060. View

Porter A, Gass M, Muller K, Skepper J, Midgley P, Welland M . Direct imaging of single-walled carbon nanotubes in cells. Nat Nanotechnol. 2008; 2(11):713-7. DOI: 10.1038/nnano.2007.347. View

Haddad F, Sawalha M, Khawaja Y, Najjar A, Karaman R . Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease. Molecules. 2018; 23(1). PMC: 5943940. DOI: 10.3390/molecules23010040. View

Bardi G, Nunes A, Gherardini L, Bates K, Al-Jamal K, Gaillard C . Functionalized carbon nanotubes in the brain: cellular internalization and neuroinflammatory responses. PLoS One. 2013; 8(11):e80964. PMC: 3832421. DOI: 10.1371/journal.pone.0080964. View

Vinardell M, Infante M . The relationship between the chain length of non-ionic surfactants and their hemolytic action on human erythrocytes. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 2000; 124(2):117-20. DOI: 10.1016/s0742-8413(99)00057-2. View

Kafa H, Wang J, Rubio N, Venner K, Anderson G, Pach E . The interaction of carbon nanotubes with an in vitro blood-brain barrier model and mouse brain in vivo. Biomaterials. 2015; 53:437-52. PMC: 4407899. DOI: 10.1016/j.biomaterials.2015.02.083. View

10.

Worle-Knirsch J, Pulskamp K, Krug H . Oops they did it again! Carbon nanotubes hoax scientists in viability assays. Nano Lett. 2006; 6(6):1261-8. DOI: 10.1021/nl060177c. View

11.

Ren J, Shen S, Wang D, Xi Z, Guo L, Pang Z . The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials. 2012; 33(11):3324-33. DOI: 10.1016/j.biomaterials.2012.01.025. View

12.

Kura A, Hussein Al Ali S, Hussein M, Fakurazi S, Arulselvan P . Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent. Int J Nanomedicine. 2013; 8:1103-10. PMC: 3604971. DOI: 10.2147/IJN.S39740. View

13.

Arnold M, Green A, Hulvat J, Stupp S, Hersam M . Sorting carbon nanotubes by electronic structure using density differentiation. Nat Nanotechnol. 2008; 1(1):60-5. DOI: 10.1038/nnano.2006.52. View

14.

Alyautdin R, Petrov V, Langer K, Berthold A, Kharkevich D, Kreuter J . Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res. 1997; 14(3):325-8. DOI: 10.1023/a:1012098005098. View

15.

Huang Y, Lin I, Chen C, Hsu Y, Chang C, Lee M . Delivery of small interfering RNAs in human cervical cancer cells by polyethylenimine-functionalized carbon nanotubes. Nanoscale Res Lett. 2013; 8(1):267. PMC: 3683344. DOI: 10.1186/1556-276X-8-267. View

16.

Tan J, Foo J, Fakurazi S, Hussein M . Release behaviour and toxicity evaluation of levodopa from carboxylated single-walled carbon nanotubes. Beilstein J Nanotechnol. 2015; 6:243-53. PMC: 4311623. DOI: 10.3762/bjnano.6.23. View

17.

Mannerstrom M, Zou J, Toimela T, Pyykko I, Heinonen T . The applicability of conventional cytotoxicity assays to predict safety/toxicity of mesoporous silica nanoparticles, silver and gold nanoparticles and multi-walled carbon nanotubes. Toxicol In Vitro. 2016; 37:113-120. DOI: 10.1016/j.tiv.2016.09.012. View

18.

Kura A, Hussein-Al-Ali S, Hussein M, Fakurazi S . Preparation of Tween 80-Zn/Al-levodopa-layered double hydroxides nanocomposite for drug delivery system. ScientificWorldJournal. 2014; 2014:104246. PMC: 3982257. DOI: 10.1155/2014/104246. View

19.

Liu Z, Davis C, Cai W, He L, Chen X, Dai H . Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc Natl Acad Sci U S A. 2008; 105(5):1410-5. PMC: 2234157. DOI: 10.1073/pnas.0707654105. View

20.

Brodell D, Stanford N, Jacobson C, Schmidt P, Okun M . Carbidopa/levodopa dose elevation and safety concerns in Parkinson's patients: a cross-sectional and cohort design. BMJ Open. 2012; 2(6). PMC: 3533055. DOI: 10.1136/bmjopen-2012-001971. View